ISIS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the historical short interest of Isis Pharmaceuticals, as measured by the Short Percentage Of Float.
This the Institutional Ownership History of Isis Pharmaceuticals Peter Lynch prefers to buy companies with low institutional ownership.
This is the historical insider ownership of Isis Pharmaceuticals. It is usually better to buy companies with large insider ownership. The company insiders' interest are more aligned with external shareholders in this case.
|Holder||Shares||% of Shares |
|Christopher F.O. Gabrieli||155,431||0.13%||2004-05-14|
|Dr. Spencer R. Berthelsen,M.D.||50,395||less than 0.1%||2014-07-01|
|Mr. Joseph H. Wender||37,217||less than 0.1%||2014-07-01|
|Dr. Douglas L. Cole,PhD||9,616||less than 0.1%||2004-03-05|
|Holmlud Jon T||7,510||less than 0.1%||2004-01-01|
|Dr. Stanley T. Crooke,M.D.,PhD||6,941||less than 0.1%||2014-10-23|
|Dr. Mark K. Wedel,M.D.,J.D.||6,603||less than 0.1%||2007-07-06|
|Karen Lundstedt||5,407||less than 0.1%||2004-03-10|
|Dr. Richard S. Geary,PhD||5,388||less than 0.1%||2014-07-01|
|Dr. C. Frank Bennett,PhD||4,627||less than 0.1%||2014-08-27|
|Holder||Shares||Report Date||% of Shares |
|% of Total |
|Fidelity Management and Research Company||17,549,733||2014-09-30||14.87||0.10||681,456,000|
|ClearBridge Advisors, LLC||8,988,756||2014-09-30||7.62||0.38||349,033,000|
|Fidelity® Growth Company Fund||8,530,097||2014-10-31||7.23||0.94||392,896,268|
|Artisan Partners Limited Partnership||7,368,499||2014-09-30||6.25||0.51||286,119,000|
|Vanguard Group, Inc.||7,257,516||2014-09-30||6.15||0.02||281,809,000|
|BB Biotech AG||6,636,526||2014-09-30||5.62||10.48||257,696,000|
|Bellevue Asset Management AG||6,636,526||2014-09-30||5.62||8.57||257,456,829|
|Bb Biotech AG||6,636,526||2014-09-30||5.62||8.57||257,456,829|
|Waddell & Reed Investment Management Co||5,494,100||2014-09-30||4.66||0.30||213,336,000|
|BlackRock Fund Advisors||4,120,458||2014-09-30||3.49||0.05||159,997,000|
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.